NYSEAMERICAN:VNRX - VolitionRX Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.86 -0.02 (-0.69 %)
(As of 02/19/2019 04:00 PM ET)
Previous Close$2.88
Today's Range$2.80 - $2.98
52-Week Range$1.44 - $3.58
Volume107,900 shs
Average Volume103,388 shs
Market Capitalization$101.06 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.

Receive VNRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:VNRX
Previous SymbolNYSEMKT:VNRX
CUSIPN/A
Phone646 650 1351

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees37
Market Cap$101.06 million
OptionableNot Optionable

VolitionRX (NYSEAMERICAN:VNRX) Frequently Asked Questions

What is VolitionRX's stock symbol?

VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

How were VolitionRX's earnings last quarter?

VolitionRX Ltd (NYSEAMERICAN:VNRX) released its quarterly earnings data on Wednesday, November, 7th. The medical research company reported ($0.14) EPS for the quarter, hitting analysts' consensus estimates of ($0.14). View VolitionRX's Earnings History.

When is VolitionRX's next earnings date?

VolitionRX is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for VolitionRX.

What price target have analysts set for VNRX?

4 Wall Street analysts have issued 1 year price objectives for VolitionRX's shares. Their forecasts range from $5.00 to $10.00. On average, they expect VolitionRX's share price to reach $6.50 in the next year. This suggests a possible upside of 127.3% from the stock's current price. View Analyst Price Targets for VolitionRX.

What is the consensus analysts' recommendation for VolitionRX?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VolitionRX.

Has VolitionRX been receiving favorable news coverage?

Media coverage about VNRX stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. VolitionRX earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are some of VolitionRX's key competitors?

Who are VolitionRX's key executives?

VolitionRX's management team includes the folowing people:
  • Dr. Martin Charles Faulkes, Exec. Chairman (Age 75)
  • Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 48)
  • Dr. Jacob Vincent Micallef Ph.D., MBA, Chief Scientific Officer (Age 63)
  • Dr. Jason Bradley Terrell, Chief Medical Officer & CEO of Volition America Inc. (Age 39)
  • Mr. Rodney Gerard Rootsaert LLB, Corp. Sec. (Age 48)

Who are VolitionRX's major shareholders?

VolitionRX's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (0.08%). Company insiders that own VolitionRX stock include Cameron John Reynolds, David Cecil Vanston and Guy Archibald Innes. View Institutional Ownership Trends for VolitionRX.

Which institutional investors are buying VolitionRX stock?

VNRX stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp. Company insiders that have bought VolitionRX stock in the last two years include Cameron John Reynolds, David Cecil Vanston and Guy Archibald Innes. View Insider Buying and Selling for VolitionRX.

How do I buy shares of VolitionRX?

Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VolitionRX's stock price today?

One share of VNRX stock can currently be purchased for approximately $2.86.

How big of a company is VolitionRX?

VolitionRX has a market capitalization of $101.06 million. VolitionRX employs 37 workers across the globe.

What is VolitionRX's official website?

The official website for VolitionRX is http://www.volitionrx.com/.

How can I contact VolitionRX?

The medical research company can be reached via phone at 646 650 1351.


MarketBeat Community Rating for VolitionRX (NYSEAMERICAN VNRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  258
MarketBeat's community ratings are surveys of what our community members think about VolitionRX and other stocks. Vote "Outperform" if you believe VNRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Featured Article: What is a stock split?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel